CONCORD BIOTECH LIMITED

Concord Biotech Limited reported a strong start to FY27, with Q1 revenues of INR257 crores, reflecting a 26% year-on-year growth. Management noted that the growth was broad-based across key product categories, including immunosuppressants, anti-infectives, oncology, and antifungals. The export business was a significant growth driver, with export revenues increasing by 46% year-on-year. Management highlighted the successful completion of regulatory inspections and approvals, which expanded their addressable market. The company also commenced commercial operations through Stellon Biotech, their distribution platform in the U.S. Financially, Q1 FY27 gross margins improved to 78.9%, and profit after tax grew by 31% to INR58 crores. Management expressed confidence in sustaining growth momentum and emphasized their commitment to long-term value creation through R&D and operational excellence.

Management emphasized strong growth and positive developments across various business segments.